156 related articles for article (PubMed ID: 32856873)
21. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
22. The Prognosis of Papillary Thyroid Cancer with Initial Distant Metastasis is Strongly Associated with Extensive Extrathyroidal Extension: A Retrospective Cohort Study.
Lee YK; Kim D; Shin DY; Lee CR; Lee EJ; Kang SW; Lee J; Jeong JJ; Nam KH; Chung WY; Park CS
Ann Surg Oncol; 2019 Jul; 26(7):2200-2209. PubMed ID: 30895495
[TBL] [Abstract][Full Text] [Related]
23. Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance.
Zhou Y; Jiang HG; Lu N; Lu BH; Chen ZH
Asian Pac J Cancer Prev; 2015; 16(4):1605-8. PubMed ID: 25743839
[TBL] [Abstract][Full Text] [Related]
24. Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers.
Maroof H; Irani S; Arianna A; Vider J; Gopalan V; Lam AK
Curr Cancer Drug Targets; 2019; 19(7):561-570. PubMed ID: 29956628
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer.
Zhao H; Huang T; Li H
Surgery; 2019 Jul; 166(1):55-60. PubMed ID: 30876667
[TBL] [Abstract][Full Text] [Related]
26. The extent of extrathyroidal extension is a key determinant of prognosis in T4a papillary thyroid cancer.
Abraham E; Roshan D; Tran B; Wykes J; Campbell P; Ebrahimi A
J Surg Oncol; 2019 Nov; 120(6):1016-1022. PubMed ID: 31452204
[TBL] [Abstract][Full Text] [Related]
27. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?
Tang J; Gui C; Qiu S; Wang M
World J Surg Oncol; 2018 May; 16(1):100. PubMed ID: 29855303
[TBL] [Abstract][Full Text] [Related]
28. Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls.
Carr AA; Yen TWF; Ortiz DI; Hunt BC; Fareau G; Massey BL; Campbell BH; Doffek KL; Evans DB; Wang TS
Thyroid; 2018 Nov; 28(11):1462-1467. PubMed ID: 30215297
[TBL] [Abstract][Full Text] [Related]
29. Risk Factors for and Prediction Model of Skip Metastasis to Lateral Lymph Nodes in Papillary Thyroid Carcinoma.
Hu D; Lin H; Zeng X; Wang T; Deng J; Su X
World J Surg; 2020 May; 44(5):1498-1505. PubMed ID: 31863139
[TBL] [Abstract][Full Text] [Related]
30. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma.
Luo D; Chen H; Lu P; Li X; Long M; Peng X; Huang M; Huang K; Lin S; Tan L; Zhu Y; Chen Z; Ouyang N; Li H
Cancer Biomark; 2017; 18(3):273-284. PubMed ID: 28009325
[TBL] [Abstract][Full Text] [Related]
31. Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.
Giaginis C; Alexandrou P; Delladetsima I; Karavokyros I; Danas E; Giagini A; Patsouris E; Theocharis S
Pathol Oncol Res; 2016 Jan; 22(1):189-96. PubMed ID: 26498465
[TBL] [Abstract][Full Text] [Related]
32. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
Xu B; Serrette R; Tuttle RM; Alzumaili B; Ganly I; Katabi N; Tallini G; Ghossein R
Thyroid; 2019 Dec; 29(12):1792-1803. PubMed ID: 31452453
[No Abstract] [Full Text] [Related]
33. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer.
Ma B; Jiang H; Wen D; Hu J; Han L; Liu W; Xu W; Shi X; Wei W; Liao T; Wang Y; Lu Z; Wang Y; Ji Q
J Clin Endocrinol Metab; 2019 Sep; 104(9):3713-3725. PubMed ID: 30942873
[TBL] [Abstract][Full Text] [Related]
34. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA ASMTL-AS1 inhibits tumor growth and glycolysis by regulating the miR-93-3p/miR-660/FOXO1 axis in papillary thyroid carcinoma.
Feng Z; Chen R; Huang N; Luo C
Life Sci; 2020 Mar; 244():117298. PubMed ID: 31953163
[TBL] [Abstract][Full Text] [Related]
36. Investigating the prevalence of risk factors of papillary thyroid carcinoma recurrence and disease-free survival after thyroidectomy and central neck dissection in Iranian patients.
Arianpoor A; Asadi M; Amini E; Ziaeemehr A; Ahmadi Simab S; Zakavi SR
Acta Chir Belg; 2020 Jun; 120(3):173-178. PubMed ID: 31237189
[No Abstract] [Full Text] [Related]
37. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
[TBL] [Abstract][Full Text] [Related]
38. Expression of cancer stem cell markers in tall cell variant papillary thyroid cancer identifies a molecular profile predictive of recurrence in classic papillary thyroid cancer.
Beck AC; Rajan A; Landers S; Kelley S; Bellizzi AM; Lal G; Sugg SL; Howe JR; Chan CH; Weigel RJ
Surgery; 2022 Jan; 171(1):245-251. PubMed ID: 34362588
[TBL] [Abstract][Full Text] [Related]
39. MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.
Sondermann A; Andreghetto FM; Moulatlet AC; da Silva Victor E; de Castro MG; Nunes FD; Brandão LG; Severino P
Clin Exp Metastasis; 2015 Aug; 32(6):521-30. PubMed ID: 26007293
[TBL] [Abstract][Full Text] [Related]
40. Loss of nuclear localization of thyroid transcription factor 1 and adverse outcomes in papillary thyroid cancer.
Lopez-Campistrous A; Thiesen A; Gill AJ; Ghosh S; McMullen TP
Hum Pathol; 2019 Sep; 91():36-42. PubMed ID: 31229486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
